Published in J Natl Cancer Inst on October 07, 1998
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst (2011) 5.09
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer (2008) 3.98
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol (2012) 3.96
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2008) 2.83
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol (1999) 2.69
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol (2010) 2.06
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget (2012) 2.03
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol (2010) 1.98
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer (2010) 1.87
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc Natl Acad Sci U S A (2007) 1.78
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
Glioma classification: a molecular reappraisal. Am J Pathol (2001) 1.65
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol (2013) 1.63
Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol (2001) 1.61
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol (2002) 1.61
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol (2007) 1.53
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med (2011) 1.52
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. Am J Pathol (2001) 1.41
Molecular diagnostics of gliomas: state of the art. Acta Neuropathol (2010) 1.40
Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer (2014) 1.37
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol (2007) 1.36
Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A (1999) 1.36
Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med Biol (2012) 1.29
Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A (2001) 1.29
Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol (2010) 1.27
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol (1999) 1.26
Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev (2014) 1.22
p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev (2003) 1.16
Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J Mol Diagn (2006) 1.16
Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol (2009) 1.16
Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol (2006) 1.15
Imaging in neurooncology. NeuroRx (2005) 1.14
Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry (2004) 1.13
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol (2009) 1.13
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res (2009) 1.11
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol (2015) 1.11
Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One (2007) 1.11
Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours. Br J Cancer (2004) 1.11
Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn (2006) 1.09
Moving toward molecular classification of diffuse gliomas in adults. Neurology (2012) 1.08
Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol (2012) 1.08
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol (2008) 1.06
Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification. Clin Cancer Res (2012) 1.06
Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One (2012) 1.05
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A (2009) 1.05
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol (2001) 1.04
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
Gliomas in adults. Dtsch Arztebl Int (2010) 1.02
Recent advancements in multimodality treatment of gliomas. Future Oncol (2011) 1.02
Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology (2006) 1.01
Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 1.01
Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch (2008) 1.01
Scission of the p53-MDM2 Loop by Ribosomal Proteins. Genes Cancer (2012) 1.00
Biology, genetics and imaging of glial cell tumours. Br J Radiol (2011) 1.00
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol (2011) 1.00
Survival analysis of patients with high-grade gliomas based on data mining of imaging variables. AJNR Am J Neuroradiol (2012) 0.99
Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr (2006) 0.99
The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev (2003) 0.98
Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One (2012) 0.98
Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC Genomics (2013) 0.98
Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br J Cancer (2003) 0.97
Modern brain tumor imaging. Brain Tumor Res Treat (2015) 0.97
Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol (2014) 0.96
DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer (2004) 0.96
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res (2015) 0.96
Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. Transl Oncol (2012) 0.95
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol (2015) 0.94
SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One (2012) 0.94
Autocrine PDGF stimulation in malignancies. Ups J Med Sci (2012) 0.94
Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol (2015) 0.93
Anaplastic oligodendroglioma. Curr Treat Options Neurol (2008) 0.93
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS One (2013) 0.93
Incidence and relative survival of anaplastic astrocytomas. Neuro Oncol (2014) 0.93
Molecular biology of gliomas: present and future challenges. Transl Med UniSa (2014) 0.92
The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol (2012) 0.92
Molecular profile of oligodendrogliomas in young patients. Neuro Oncol (2011) 0.92
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol (2004) 0.91
Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus (2015) 0.91
Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol (2012) 0.90
Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol (2009) 0.90
Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev (2009) 0.90
Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol (2004) 0.90
Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol (2013) 0.88
Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging (2015) 0.88
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia (2005) 0.88
Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours. J Neurol Neurosurg Psychiatry (2004) 0.88
Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol (2010) 0.88
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics (2000) 6.19
Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature (1994) 5.33
Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol (2000) 5.28
PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42
Computer-based interview for screening blood donors for risk of HIV transmission. JAMA (1992) 4.01
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest (1998) 3.76
Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet (1997) 3.66
A proportional hazards model for interval-censored failure time data. Biometrics (1986) 3.64
Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest (1999) 3.36
Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology (1994) 3.19
Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet (1999) 3.15
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med (1996) 3.04
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell (1998) 2.77
Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol (1998) 2.62
Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia (2007) 2.48
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Risk of rupture from incidental cerebral aneurysms. J Neurosurg (2000) 2.30
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res (2001) 2.28
Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28
Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest (1999) 2.27
Five cases of ectopic liver and a case of accessory lobe of the liver. Endoscopy (1989) 2.24
Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature (1997) 2.20
Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation (1993) 2.20
Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol (1995) 2.19
Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol (2001) 2.14
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol (2011) 2.13
Matrix/integrin interaction activates the mitogen-activated protein kinase, p44erk-1 and p42erk-2. J Biol Chem (1995) 2.09
VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease. Neurology (1999) 2.08
PTEN mutations in gliomas and glioneuronal tumors. Oncogene (1998) 2.01
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med (1997) 1.97
Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol (1997) 1.95
Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol (1996) 1.95
Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg (1999) 1.92
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg (2000) 1.82
Snowboard head injury: prospective study in Chino, Nagano, for two seasons from 1995 to 1997. J Trauma (1999) 1.79
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int (2001) 1.77
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol (1986) 1.76
Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst (1992) 1.70
Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem (2000) 1.67
Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol (1993) 1.67
Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem (2000) 1.67
Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Neurology (1996) 1.66
Intramedullary cavernous angiomas of the spinal cord: clinical presentation, pathological features, and surgical management. Neurosurgery (1992) 1.65
Superiority of quantitative exercise thallium-201 variables in determining long-term prognosis in ambulatory patients with chest pain: a comparison with cardiac catheterization. J Am Coll Cardiol (1988) 1.65
Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol (1988) 1.64
Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol (2001) 1.63
Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet (1994) 1.62
Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg (2001) 1.60
Familial schwannomatosis: exclusion of the NF2 locus as the germline event. Neurology (2003) 1.57
Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem (1992) 1.57
Results of radiosurgery for brain stem arteriovenous malformations. J Neurol Neurosurg Psychiatry (2000) 1.56
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys (1992) 1.54
Analysis of treatment outcome after stereotactic radiosurgery for cavernous sinus meningiomas. J Neurosurg (2001) 1.53
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer (1994) 1.52
The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol (1996) 1.51
Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol (1993) 1.50
Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery (2000) 1.49
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology (2011) 1.48
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res (1992) 1.48
Clinicopathological study of intracranial fusiform and dolichoectatic aneurysms : insight on the mechanism of growth. Stroke (2000) 1.48
PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci (2001) 1.47
Analysis of mtDNA sequences shows Japanese native chickens have multiple origins. Anim Genet (2007) 1.47
NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol (2001) 1.47
Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology (2001) 1.47
High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer (1997) 1.46
Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res (1996) 1.44
Molecular pathways in the formation of gliomas. Glia (1995) 1.43
Measuring bias in uncontrolled brain tumor trials--to randomize or not to randomize? Can J Neurol Sci (1997) 1.43
Alzheimer's disease and spirochetes; a questionable relationship. Neuroreport (1993) 1.41
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene (2006) 1.41
Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet (2001) 1.39
A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics (2000) 1.39
Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1998) 1.39
Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci U S A (2000) 1.39
Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res (2001) 1.38
Risk of aneurysm recurrence in patients with clipped cerebral aneurysms: results of long-term follow-up angiography. Stroke (2001) 1.38
Design considerations for AIDS trials. N Engl J Med (1990) 1.38
The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol (1994) 1.37
Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol (1997) 1.37